Saturday 17 October 2026
Export SLDB’s income statement to Excel — free account
Solid Biosciences Inc.
SLDB Healthcare Biotechnology
Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million. In the quarter to June 2026, EPS grew 9.52% and free cash flow fell 39.6%, each against the same quarter a year earlier.
5.53
0.21
−3.66%
Follow SLDB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (65.50%) | (57.37%) | (109.90%) | (86.83%) |
+8 more TTM periods Free account |
|
| (56.83%) | (50.02%) | (82.78%) | (68.82%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(55.90%) | (51.77%) | (98.96%) | (78.52%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.31) | (1.57) | (1.80) | (1.41) | |
Free Cash Flow |
(187.72) | (172.78) | (157.36) | (133.17) | |
Capital Expenditures |
(0.88) | (1.11) | (1.07) | (0.79) | |
| Other line items | |||||
Cash ROIC |
(24.95%) | (22.87%) | (42.63%) | (29.33%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | 882.79 | 1,275.93 | |
Operating CF/Net income |
0.90 | 0.90 | 0.90 | 0.79 | |
Depreciation/Fixed assets |
(0.36) | (0.14) | (0.06) | (0.06) | |
Capex/Depreciation |
0.62 | 1.99 | 4.49 | 2.88 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.30) | (1.56) | (1.79) | (1.40) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates